By News Staff
The FDA granted a new indication for riluzole (Tiglutik, ITF Pharma) oral suspension to include administration by percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of amyotrophic lateral sclerosis (ALS).
This approval expands the patient population to include individuals whose swallowing difficulty is complicated by alterations in nutritional status, necessitating the use of a PEG feeding tube.